JP2018529671A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529671A5
JP2018529671A5 JP2018511491A JP2018511491A JP2018529671A5 JP 2018529671 A5 JP2018529671 A5 JP 2018529671A5 JP 2018511491 A JP2018511491 A JP 2018511491A JP 2018511491 A JP2018511491 A JP 2018511491A JP 2018529671 A5 JP2018529671 A5 JP 2018529671A5
Authority
JP
Japan
Prior art keywords
compound
salt
pharmaceutically acceptable
phosphoryl
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018511491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529671A (ja
JP6743135B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/049873 external-priority patent/WO2017040766A1/en
Publication of JP2018529671A publication Critical patent/JP2018529671A/ja
Publication of JP2018529671A5 publication Critical patent/JP2018529671A5/ja
Application granted granted Critical
Publication of JP6743135B2 publication Critical patent/JP6743135B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018511491A 2015-09-02 2016-09-01 抗ウィルス性テトラヒドロフラン誘導体 Expired - Fee Related JP6743135B2 (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201562213378P 2015-09-02 2015-09-02
US62/213,378 2015-09-02
US201562242136P 2015-10-15 2015-10-15
US62/242,136 2015-10-15
US201562253426P 2015-11-10 2015-11-10
US62/253,426 2015-11-10
US201662294449P 2016-02-12 2016-02-12
US62/294,449 2016-02-12
US201662296801P 2016-02-18 2016-02-18
US62/296,801 2016-02-18
US201662321538P 2016-04-12 2016-04-12
US62/321,538 2016-04-12
US201662327087P 2016-04-25 2016-04-25
US62/327,087 2016-04-25
US201662351038P 2016-06-16 2016-06-16
US62/351,038 2016-06-16
US201662363640P 2016-07-18 2016-07-18
US62/363,640 2016-07-18
US201662375029P 2016-08-15 2016-08-15
US62/375,029 2016-08-15
PCT/US2016/049873 WO2017040766A1 (en) 2015-09-02 2016-09-01 Anti-viral tetrahydrofurane derivatives

Publications (3)

Publication Number Publication Date
JP2018529671A JP2018529671A (ja) 2018-10-11
JP2018529671A5 true JP2018529671A5 (cg-RX-API-DMAC7.html) 2019-11-21
JP6743135B2 JP6743135B2 (ja) 2020-08-19

Family

ID=56926317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511491A Expired - Fee Related JP6743135B2 (ja) 2015-09-02 2016-09-01 抗ウィルス性テトラヒドロフラン誘導体

Country Status (7)

Country Link
US (2) US9676797B2 (cg-RX-API-DMAC7.html)
EP (1) EP3344642A1 (cg-RX-API-DMAC7.html)
JP (1) JP6743135B2 (cg-RX-API-DMAC7.html)
CN (1) CN108350016B (cg-RX-API-DMAC7.html)
CA (1) CA2997170A1 (cg-RX-API-DMAC7.html)
MX (1) MX2018002707A (cg-RX-API-DMAC7.html)
WO (1) WO2017040766A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX382566B (es) * 2015-05-01 2025-03-13 Univ Emory Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer
JP6743135B2 (ja) * 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
US20190358214A1 (en) * 2016-11-17 2019-11-28 Abbvie Inc. Compositions and Methods for Treating HCV Infection
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
WO2019139920A1 (en) * 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN109762040A (zh) * 2019-01-14 2019-05-17 歌礼生物制药(杭州)有限公司 一种核苷类ns5b聚合酶抑制剂的制备方法
EP3999519A4 (en) 2019-07-17 2023-08-16 Nucorion Pharmaceuticals, Inc. CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS
CN115605492B (zh) 2020-04-21 2025-09-16 配体制药股份有限公司 核苷酸前药化合物
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5246924A (en) 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US6060542A (en) 1997-05-16 2000-05-09 Shell Oil Company Bitumen compositions and a process for their preparation
DE69933860T2 (de) 1998-02-25 2007-05-31 Emory University 2'-fluoronukleoside
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
ATE275406T1 (de) 2000-05-26 2004-09-15 Idenix Cayman Ltd Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1330459B1 (en) * 2000-10-02 2006-08-02 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
PT2251015E (pt) 2000-10-18 2013-04-15 Gilead Pharmasset Llc Nucleosídeos modificados para o tratamento de infeções virais e de proliferação celular anormal
BR0206614A (pt) 2001-01-22 2004-02-17 Merck & Co Inc Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
CA2488842A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Carbocyclic nucleoside analogs as rna-antivirals
WO2004000858A2 (en) 2002-06-21 2003-12-31 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP2005533824A (ja) 2002-06-28 2005-11-10 イデニクス(ケイマン)リミテツド フラビウイルス科感染の治療のための2’−c−メチル−3’−o−l−バリンエステルリボフラノシルシチジン
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7824851B2 (en) 2002-11-15 2010-11-02 Idenix Pharmaceuticals, Inc. 2′-branched nucleosides and Flaviviridae mutation
EP1585529A4 (en) 2002-12-12 2008-05-28 Idenix Cayman Ltd PROCESS FOR PREPARING 2'-BRANCHED NUCLEOSIDES
US7582748B2 (en) * 2003-03-20 2009-09-01 Microbiologica Quimica E Farmaceutical Ltd. Methods of manufacture of 2′-deoxy-β-L-nucleosides
ES2586668T5 (es) 2003-05-30 2024-11-12 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US8399428B2 (en) 2004-12-09 2013-03-19 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) * 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
CN103819459B (zh) 2009-06-11 2017-05-17 艾伯维巴哈马有限公司 抗病毒化合物
US9790252B2 (en) 2009-07-01 2017-10-17 Cornell University 2-fluorinated riboses and arabinoses and methods of use and synthesis
EP2789614B1 (en) * 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
US9700560B2 (en) 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
LT2609923T (lt) * 2010-03-31 2017-09-11 Gilead Pharmasset Llc (s)-izopropilo 2-(((s)-(perfluorfenoksi)(fenoksi)fosforil)amino)-propanoato kristalinimo būdas
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
CA2830689A1 (en) * 2011-04-13 2012-10-18 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
PE20140522A1 (es) 2011-04-13 2014-05-03 Merck Sharp & Dohme Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
HUE033332T2 (en) * 2011-12-20 2017-11-28 Riboscience Llc 4'-Azido-3'-fluoro-substituted nucleoside derivatives as inhibitors of HCV RNA replication
SG11201403364PA (en) * 2011-12-20 2014-07-30 Hoffmann La Roche 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
WO2013187978A1 (en) * 2012-06-16 2013-12-19 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN102751200B (zh) 2012-06-29 2015-06-10 京东方科技集团股份有限公司 薄膜晶体管、阵列基板及其制造方法
US20140065101A1 (en) * 2012-08-31 2014-03-06 Novartis Ag 2'-Branched Nucleosides for Treatment of Viral Infections
HK1207647A1 (en) 2012-10-08 2016-02-05 Idenix Pharmaceuticals Llc 2'-chloro nucleoside analogs for hcv infection
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
EA201590943A1 (ru) 2012-12-21 2016-01-29 Алиос Биофарма, Инк. Замещенные нуклеозиды, нуклеотиды и их аналоги
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
AU2014250764A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating HCV
ES2952714T3 (es) 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
SG10201804835VA (en) 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US20160271160A1 (en) 2013-10-17 2016-09-22 Medivir Ab Hcv polymerase inhibitors
WO2015077360A2 (en) * 2013-11-20 2015-05-28 Idenix Pharmaceuticals, Inc. Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3102188A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
EP3134423A4 (en) 2014-04-24 2017-11-29 Cocrystal Pharma, Inc. 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
EP3212658A4 (en) 2014-10-31 2018-07-25 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX382566B (es) * 2015-05-01 2025-03-13 Univ Emory Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer
JP6743135B2 (ja) * 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体

Similar Documents

Publication Publication Date Title
JP2018529671A5 (cg-RX-API-DMAC7.html)
RU2016138735A (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
EA022127B1 (ru) Ингибиторы вируса гепатита с
JP2020183410A5 (cg-RX-API-DMAC7.html)
JP2020504733A5 (cg-RX-API-DMAC7.html)
RU2016122908A (ru) Соединения дигидропиримидина и их применение в фармацевтических препаратах
JP2010525056A5 (cg-RX-API-DMAC7.html)
HRP20151075T1 (hr) Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino) propanoat
JP2024156774A5 (cg-RX-API-DMAC7.html)
JP2014508804A5 (cg-RX-API-DMAC7.html)
JP2009535352A5 (cg-RX-API-DMAC7.html)
JP2016538313A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2017523225A5 (cg-RX-API-DMAC7.html)
NZ582089A (en) Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
JP2015514806A5 (cg-RX-API-DMAC7.html)
JP2014513110A5 (cg-RX-API-DMAC7.html)
JP2015529652A5 (cg-RX-API-DMAC7.html)
JP2010532747A5 (cg-RX-API-DMAC7.html)
JP2016523974A5 (cg-RX-API-DMAC7.html)
JP2021500394A5 (cg-RX-API-DMAC7.html)
JP2010500414A5 (cg-RX-API-DMAC7.html)
JP2010504346A5 (cg-RX-API-DMAC7.html)
JP2012528161A5 (cg-RX-API-DMAC7.html)
RU2013112744A (ru) Алкил 2-{[(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)-гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино}-пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения